Showing results (81-90 of 112) with videos related to
Sort By:
Pageof 12
The Lancet. Oncology|February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.The Lancet. Oncology|April 5, 2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2021
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single InstitutionVincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.Cancers|April 3, 2021
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma GroupEmanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.Frontiers in Oncology|December 26, 2022
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysisEmanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.The Lancet. Oncology|May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.The New England Journal of Medicine|October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.Pageof 12